Replies to post #13411 on GT Biopharma Inc (GTBP)

[GunHawk]

OXS-3550 for liquid tumors. The TRiKE platform has shown promising in vivo data compared to BiKEs. (The addition of Il-15 created NK cell proliferation resulting in 60-70% remission vs 30-50% for BiKE)